Topical TYK2/JAK 1 inhibitor effective and tolerable in mild-to-moderate AD

There is a high medical need for patients with mild-to-moderate atopic dermatitis (AD). According to a phase 2b study, brepocitinib cream could be an interesting novel option for these patients. The brepocitinib cream showed a significant decrease in EASI score at week 6 compared with a vehicle cream, as well as a higher rate of EASI 90 response and a fast and significant antipruritic effect. The topical tyrosine kinase (TYK)2/Janus kinase (JAK)1 inhibitor brepocitinib is a single-molecule designed to target 2 key pathways that play a role in ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 3 November, 202018 December, 2020